JNJ-79635322 — Investigational Agent
T-Cell Engager · Phase 1/2 · Janssen / Johnson & Johnson
Mechanism of Action
Trispecific T-cell-engaging antibody targeting both BCMA and GPRC5D on myeloma cells while engaging CD3 on T cells, providing dual tumor-antigen targeting to reduce antigen-escape relapse.
Investigational Indications
- Relapsed/refractory multiple myeloma
- Previously treated AL amyloidosis